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Am J Med Genet Part A 167A:1962–1971.Turner syndrome, a congenital condition that affects 1/2,500
births, results fromabsence or structural alteration of the second
sex chromosome. There has been substantial effort by numerous
clinical and genetic research groups to delineate the clinical,
pathophysiological, cytogenetic, and molecular features of this
multisystem condition. Questions about the molecular-genetic
and biological basis of many of the clinical features remain
unanswered, and health care providers and families seek im-
proved care for affected individuals. The inaugural “Turner
Resource Network (TRN) Symposium” brought together indi-
viduals with Turner syndrome and their families, advocacy
group leaders, clinicians, basic scientists, physician-scientists,
trainees and other stakeholders with interest in the well-being of
individuals and families living with the condition. The goal of
this symposium was to establish a structure for a TRN that will
be a patient-powered organization involving those living with
Turner syndrome, their families, clinicians, and scientists. The
TRN will identify basic and clinical questions that might be
answered with registries, clinical trials, or through bench re-
search to promote and advocate for best practices and improved
care for individuals with Turner syndrome. The symposium
concluded with the consensus that two rationales justify the
creation of a TRN:
1. inadequate attention has been paid to the health and psycho-
social issues facing girls and women who live with Turner
syndrome;
2. investigations into the susceptibility to common disorders
such as cardiovascular or autoimmune diseases caused by sex
chromosome deficiencies will increase understanding of dis-
ease susceptibilities in the general population.
 2015 Wiley Periodicals, Inc.
Key words: monosomy X; Turner syndrome; women; con-
genital heart disease; genetics; neurodevelopment; chromosome;
sex chromosomes; women’s health; quality of life
INTRODUCTION
The First Turner Resource Network (TRN) Symposium was held
July 13–14, 2014 in Jacksonville, Florida in conjunction with the
27th Annual Conference of the Turner Syndrome Society of the
United States (TSSUS). The symposium brought together adults
and children with Turner syndrome, their families, and represen-
tatives from other Turner syndrome support and advocacy groups,
including the Turner Syndrome Foundation and the Turner Syn-
drome Global Alliance, clinicians and basic scientists, trainees and
other stakeholders. Amajor theme of the gathering was to highlight
the considerable accomplishment of the Turner syndrome com-
munity itself. Participants included women living with Turnersyndrome from all walks of life including mothers, daughters,
lawyers, judges, administrators, pediatricians, internists, endocri-
nologists, clinical geneticists, and psychologists among others. By
virtue of the free exchange of ideas that occurred during the two-
day event, these advocates challenged and engaged the entire group
of more than 200 participants.
Prior to the meeting, a survey developed by the Advocacy
Committee of the TRN was distributed to the members of the
Turner Syndrome Society of the United States, and gathered
responses from more than 700 individuals. The survey results
were a focal point of the symposium and will direct the activities
of the TRN going forward.
The symposium itself had three closely interrelated goals:1. To identify the major health policy issues facing girls and
women living with Turner syndrome (Session I, “Health Care
Policy and Health Care Delivery for TS Patients”);2. To review basic and clinical questions thatmight be answered by
either bench research, clinical trials, clinical datasets or registries
(Session II, “Turner Science: From Genotype to Phenotype”);
and3. To discuss a strategy for how a national network of regional
Turner syndrome resource centers (the TRN) will be organized
(“Session III: The TRN roadmap”).
Turner syndrome is a rare heterogeneous condition caused by
absence of all or part of the second sex chromosome in at least a
proportion of the body’s cells in individuals with a female
phenotype. How underlying mechanisms related to X monosomy
at the level of individual tissues bring about the varied pheno-
typic features remains largely unknown. Importantly, the impact
of the genetic deficiencies on numerous body systems creates
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that society and the U.S. health care system in general have barely
begun to address. These problems include ovarian insufficiency,
infertility, and problems with the lymphatic system. In addition,
there is an increased prevalence of numerous common condi-
tions that affect the general public, including cardiovascular
disease, hypertension, stroke, and autoimmune dysfunction.
Many girls and women with Turner syndrome have to deal
with chronic and recurrent otitis media, conductive and senso-
rineural hearing impairment, orthopedic and dental issues and
some also must address neuropsychological problems that in-
clude learning disability, executive function dysregulation and
specific areas of cognitive and social challenge. Compelling
epidemiological evidence indicates a threefold higher death
rate (primarily due to cardiovascular causes) in women with
Turner syndrome compared to the risk for the general female
population at the equivalent age (Fig. 1) [Schoemaker et al.,
2008].
Two rationales have energized the stakeholders tomake the TRN
initiative a success:1. Unacceptable levels of morbidity/mortality and the lack of
access comprehensive health care among girls and women living
with Turner syndrome must be addressed, and2. Susceptibility to common conditions caused by deficiencies of
X/Y-chromosomal genes will lead to an understanding of
disease susceptibilities in the general population.
This novel second rationale was introduced during the first
morning of the symposium by Dr. David C. Page, the Director of
the Whitehead Institute and a Professor at the Massachusetts
Institute of Technology. A summary of Dr. Page’s comments
provided here is followed by a summary of the meeting presenta-FIG. 1. Cumulative risk of death from all causes and from
circulatory disease observed in the cohort of patients with
Turner syndrome and risk expected based on general population
rates for females (reproduced with permission Schoemaker and
other 2008).tions (Section II), speakers’ abstracts (Section III) and a TRN
roadmap (Section IV, breakout sessions).How Understanding Turner Syndrome Will Teach
us About Health and Disease in the General
Population. David C. Page, MD
The question of Turner syndrome’s origin is farmore complex than
it may seem, and answering it will lead us to a broader under-
standing of the role of the sex chromosomes in health and disease.
Turner syndrome was equated with monosomy X in 1959, and to
this day, it is still considered to be a chromosomal anomaly.
However, when Henry Turner and Otto Ullrich first defined the
disorder in the 1930s, they were not describing a chromosomal
anomaly but a clinical phenotype. To fully understand the interplay
between this chromosomal anomaly and the complex Turner
phenotype, we need to disentangle several related questions. We
could begin by asking: What causes monosomy X? When during
sex cell or embryonic development does the loss of the second sex
chromosome occur? We now know that most females with Turner
syndrome have a chromosome anomaly in only a subset of their
cells and tissues. Moreover, not everybody with Turner syndrome
has monosomy X. The diagnosis actually refers to a grab bag of
clinical anomalies in combination with the absence of all or part of
a second sex chromosome, either the X or the Y. We are now in the
position to ask a different question: How does the absence of all or
part of a second sex chromosome result in the clinical features of
the syndrome described by Henry Turner and Otto Ullrich?
Asking this question creates a connection between the study of
Turner syndrome and broader research on how genetic and molec-
ular differences between males and females lead to differences in
health and disease. In 1993,my laboratory colleagues and I, hypoth-
esized that the phenotypic features of Turner syndrome result from
having just a single dose (rather than a double dose) of genes that are
common to the X and Y chromosomes and that escape X inactiva-
tion[Watanabeetal., 1993;Zinnetal., 1993].Duringmostof the two
decades since, and indeed until very recently, progress in this area
had been slow; even today, studies of the sex chromosomes lag
behind the rest of the genome. Most notably, researchers pursuing
genetic understanding through genome wide association studies
(GWAS) hadmostly excluded the X and Y chromosomes from their
investigations, largely for technical reasons.
I envision an opportunity for the sex chromosomes to return to a
place of prominence in our understanding of health and disease.
When you compare an XYmale to an XX female, they are only 98.5
percent the same in their genomes: 15 times the genetic difference
when comparing two males or two females. These differences may
manifest themselves phenotypically. For example, the incidence of
rheumatoid arthritis is 2–3 times greater in women than in men.
Five boys are affected by autism spectrum disorder for every girl
who is diagnosed. The ratio of females to males diagnosed with
lupus is six to one. In the case of dilated cardiomyopathy, affected
men tend to die about 10 years earlier than affectedwomen. In none
of these cases is the disease related to the reproductive tract, but
should ultimately be accounted for by sex chromosomal differences
between XY males and XX females.
BACKELJAUW ET AL. 1965Tounderstand our sex chromosomesmore deeply, wemust turn
to evolution. The human X and Y chromosomes evolved from an
identical pair of autosomes. TheX chromosomehas retained nearly
all of the 649 genes present on the ancestral autosomes, while the Y
chromosomehas retained only 17. The 17 survivors, shared by both
the X and Y chromosomes today, turn out to be involved in
regulating the activity of other genes throughout our entire genome
[Bellott et al., 2014].We have strong evidence that 12 of these genes
are needed in two copies—one in each of the two sex chromosomes
present in XX or XY cells—to function properly. It is likely that
Turner syndrome patients, lacking a second sex chromosome,
manifest disease because of the haploinsufficency of these 12 genes.
We should be able to account for the genetic varieties of Turner
syndrome by understanding these genes shared by the X and Y
chromosomes. In addition, an understanding of the genetic basis of
disease susceptibility caused by deficiencies of the second sex
chromosome will help us to understand the panoply of differences
between men and women in health and disease. In sum, I suggest
that we forge strong links between research on Turner syndrome
and research on sex differences in disease generally.SHORT SUMMARIES OF MEETING PRESENTATIONS
(ABSTRACTS FROM EACH PRESENTATION ARE
PROVIDED BELOW AND AN eBOOK CONTAINING
THE ENTIRE PROCEEDINGS IS PLANNED FOR
PUBLICATION SUMMER 2015)
Dr. Stephen D. Chernausek discussed the future of health care for
patients with Turner syndrome and the role of patient advocates,
doctors, and the performance of translational research in the
current environment. He focused on both expanding the manner
in which health care could be delivered across the spectrum of age,
and the heterogeneity of clinical issues that girls and women face.
Dr. Carolyn Bondy reviewed the most current clinical guidelines
for the care of girls and women with Turner syndrome [Bondy and
Turner Syndrome Study, 2007] with the future goal of updating
these guidelines, especially in the area of cardiovascular imaging
and prenatal diagnosis. Dr. David Sandberg focused on health care
access and the barriers in the health care system, particularly in the
areas of behavioral health and the transition frompediatric to adult
care [Conway 2009; Devernay et al., 2009; American Academy of
Pediatrics, 2011; Crowley et al., 2011]. Dr. Gary A. Lorigan
presented the results of a survey that was submitted to the TSSUS
membership. Of 4,147 potential respondents Dr. Lorigan received
385 responses from women living with Turner syndrome and 417
responses from parents/guardians. Their concerns included social
and psychological issues as well as educational and vocational
challenges. The major medical issues facing Turner syndrome
patients included cardiovascular, endocrinological, and hearing
problems. Dr. Philippe B. Backeljauw presented the results of the
work from a professional panel that discussed the important
components of a regional Turner resource center and the logistics
of how such centers might be structured with larger more estab-
lished programs collaborating with local clinics. Dr. Nelly Mauras
presented her study related to the type and route of administrationof estrogen replacement in girls with Turner syndrome [Torres-
Santiago et al., 2013] as both a model of the type of research that
could be done by the TRN, as well as how the data might influence
guidelines for future care. Dr. Rebecca Knickmeyer presented
evidence that girls and women with Turner syndrome have critical
differences in key components of neural circuits for social cogni-
tion and working memory [Knickmeyer, 2012]. Dr. David Hong
pointed out that while intelligence is normal, and verbal skills are
enhanced for those living with Turner syndrome, visual spatial
skills, executive function, arithmetic, and social cognition are at
risk [Green et al., 2014]. Dr. Siddharth K. Prakash presented the
results of a genome-wide association study describing preliminary
evidence that modifier genes are present on chromosomes 4, 18,
and 22 that may account for the high frequency of bicuspid aortic
valve in Turner syndrome. Dr. Carolyn Bondy presented a large
body of work from the National Institute of Child Health and
Human Development natural history study which included nearly
500 girls and women with Turner syndrome, focusing on the
congenital anatomic findings. There appear to be biological differ-
ences in rates of atherosclerotic heart disease between those women
who carry a maternal X chromosome (increased risk) versus those
with a paternal X chromosome (lower risk) [Abd-Elmoniem et al.,
2014]. Dr. Paul Kruszka described work being done at the Medical
Genetics Branch of the National Institutes of Health on the genetic
underpinnings of congenital heart disease in Turner syndrome,
including whole exome sequencing studies and the development of
an animal model. Dr. Victoria Pemberton discussed the challenges
of conducting human-based research in rare conditions.
Networks or “Collaboratories,” composed of multiple research
centers, will be necessary to recruit adequate numbers of subjects
for future research. Dr. David Cole discussed the challenges to
funding an organization like the TRN in an era of diminished
federal investment in medical science. A key to the TRN’s success
will be empowerment through the patients living with Turner
syndrome and their families. An important strength of the TRN
steering committee will be the direct participation of all the
stakeholders, with patient advocates taking the lead.SPEAKERS’ ABSTRACTS
Health Care Policy and Health Care Delivery for
TS Patients
The future of health care in the USA: Patient advocates,
doctors, and translational research. Steven D. Chernausek,
MD. Henry Turner, an internist, described the clinical features
of Turner syndrome in 1938. Initially, medical care for patients
with Turner syndrome focused on making the diagnosis, detecting
associated anomalies, treating hypogonadism, and maximizing
final adult stature. For the latter, low dose oxandrolone was given
in late childhoodwith estrogen, replacement typically delayed until
the age of 14 or 15 years to extend the growth period. In the 1980s
the development of recombinant human growth hormone (rhGH)
changed the approach to increasing height. Turner syndrome was
the first non-growth hormone-deficient condition in which the
efficacy of rhGH was formally examined with randomized, con-
trolled trials, and treatment was subsequently implemented as
TABLE I. Selected Barriers to Full Implementation of Turner
Syndrome Clinical Practice Guidelines
Internal External Cross-institutional
integration/coordination location standardization
“team” care cost/insurance practice guidelines
behavioral health transition
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deal with Turner syndrome more comprehensively. In the last 10–
15 years, the emphasis of care shifted from dealing with the growth
deficit, to applying advanced reproductive technology allowing live
births, detecting and dealing with potential catastrophic cardio-
vascular disease (CVD), and addressing long-term health issues. It
is now apparent that there is significant excess mortality in adult
women with Turner syndrome, half of which is attributed to CVD.
While CVD complications typically manifest during adult life, the
problems begin during childhood, and must be addressed first by
pediatric endocrinologists and cardiologists, then transitioned to
adult practitioners. Smooth transition from pediatric to adult care
is key to maintaining appropriate surveillance for comorbidities
and optimal delivery of health care to women with Turner syn-
drome. The challenge now is to incorporate the new approaches to
clinical care, to deal with the problems of transition, and to apply
the most modern genetic methodologies that will address impor-
tant health concerns in this population.
Turner syndrome guidelines revisited. Carolyn Bondy, MS,
MD. Since the 2007 NIH Consensus Conference on guidelines
on diagnosis and care for patients with Turner syndrome, [Bondy
and Turner Syndrome Study, 2007]major developments in genetic
diagnosis and cardiac imaging technologies have emerged. Com-
mercially marketed genomic testing kits claim detection of Turner
syndrome and other chromosomal anomalies prenatally as early as
10 weeks of pregnancy. However, the American College of Obstet-
rics and Gynecology requires confirmation by standard prenatal
cytogenetic testing [Genetics 2013]. The concern is that parental
distress will lead to ill-informed terminations of early pregnancies.
Current American College of Medical Genetics guidelines for
diagnosis of Turner syndrome requires standard cytogenetic kar-
yotype analysis. DNA-sequencing or DNA-array analyses from
spot samples of saliva or blood suggest less laborious tests may
be useful [Gregg et al., 2013]. More study is needed to demonstrate
the reliability of these newer techniques. Advances in cardiovascu-
lar magnetic resonance imaging (cMRI) show that up to 25% of
significant aortic abnormalities in Turner syndrome are not de-
tectable by routine echocardiography. Thus, cMRI for all girls with
Turner syndrome at an early age or at the time of diagnosis in older
patients should be considered. Individuals who have aortic disease
are at risk for complications, including aortic valve dysfunction and
thoracic aortic dissection or rupture [Carlson et al., 2012]. It will be
important to define which patients require close monitoring and
counseling regarding safe levels of activity or attempting pregnan-
cy. Treating toddlers with growth hormone (rhGH) may prevent
growth from falling below the normal range and potentially reduce
the duration and dosage of rhGH treatment. Treatment at a
younger age may be important to optimize long-term height
outcome. Because most of the data supporting the efficacy and
safety of rhGH treatment in Turner syndrome derive from girls
treated from approximately age 7, earlier treatment and/or longer
duration need validation by additional controlled studies. Another
area of active study is the timing of initiation of estrogen treatment,
and the value of transdermal application of 17-beta estradiol versus
varied forms of oral estrogen treatment.
Barriers to health care access for patients with Turner syn-
drome. David E. Sandberg, PhD. Turner syndrome is welldescribed from a clinical standpoint. Clinical practice guidelines
provide guidance regarding details of screening for problems at the
time of diagnosis as well as the need for ongoing monitoring. The
distinction between what is recommended and what is achieved is
nowhere more apparent than in the coordination of the multiple
specialty services involved in caring for those affected with Turner
syndrome and their families. The barriers to delivering evidence-
based comprehensive and integrated health care services can be
classified as intra-institutional, extra-institutional, and cross-in-
stitutional (Table I). At the institutional level, integration, coordi-
nation, and continuity of care loom large as barriers to optimal
health outcomes. Providers in an interdisciplinary team meet
regularly to discuss and collaboratively set treatment goals for
the patients and jointly carry out the treatment plans. A key barrier
to interdisciplinary care is the lack of availability of certain spe-
cialties, in particular, behavioral health, either because of scarcity of
this resource at the institution, or because of limited reimburse-
ment. Extra-institutional barriers include factors such as the
geographic location of interdisciplinary health care teams for
Turner syndrome, generally found in tertiary care centers. Insur-
ance coverage and its cost represent additional potential barriers to
interdisciplinary team care. Although the U.S. Patient Protection
andAffordable Care Act of 2010 expanded health care coverage and
prohibited the practice of excluding coverage for those with
preexisting conditions, insurance providers may still restrict deliv-
ery of services to preferred in-network providers and facilities that
are unable to assemble the expertise required for optimal care for
patients with complex health care needs such as those with Turner
syndrome. Furthermore, effective implementation of transition of
health care services from pediatric to adult providers remains
elusive.
Finally, “cross-institutional” barriers in this context refer to
limited standardization in the process of diagnosis, description of
the Turner syndrome phenotype and variability in clinical man-
agement practices across health care centers. Electronic health
records offer the opportunity to enhance the process of standardi-
zation and reduce variability in practice. Movement in this direc-
tion not only provides the possibility to improve the quality of care
and outcomes for the individual patient, but the standardization
that would flow from such initiatives could also serve as a scalable
platform for clinical research involving a national network of
clinical teams focused on Turner syndrome.
Summary of advocacy panel poll of members of the Turner
syndrome community, Gary A. Lorigan PhD. A survey was
sent out to 4,147 members of the Turner syndrome community.
The purpose of the survey was to answer the following three
questions:
BACKELJAUW ET AL. 19671. What are the major health and well-being issues facing girls and
women living with Turner syndrome?2. What is needed to ensure care for patients with Turner syn-
drome through the transition period into adulthood?3. What are the barriers to better health and wellness for people
living with Turner syndrome?
The survey’s structure separated respondents into two catego-
ries: women with Turner syndrome and adults caring for girls
with Turner syndrome under the age of 18. There were 385
responses from women 18–70þ years of age, and 417 responses
from parents or guardians of girls with Turner syndrome under
age 18. The four major medical concerns overall were endocrine,
growth rate (for those under 18 years), cardiovascular, and
hearing/ear. The major psychological/social issues were age-de-
pendent, but included short stature, anxiety, educational chal-
lenges, poor motor skills, attention deficit, sexual function, low
self-esteem, and social interactions. Other important issues in-
cluded employment challenges, driving, and depression. The
major health maintenance issues were lack of knowledgeable
providers for needs of individuals with Turner syndrome, over-
sight of all healthcare components, and online access to resources
for patients with Turner syndrome. For access to clinical care, the
majority of respondents want a clinic no more than three hours
away, which is a significant problem given the lack of existing
centers or clinics for Turner syndrome across the U.S. Forty
percent of the women with Turner syndrome surveyed wanted
access to a specialized clinic/center, and 35% said that they
wanted a primary care physician who was knowledgeable in
health concerns related to Turner syndrome. About 50% of adult
respondents said they would be willing to continue their care in a
pediatric facility if it ensured that care would come from a
knowledgeable provider. The cost of health care and insurance
were of concern to the majority of respondents. The surveys
indicate the need for more research into issues and concerns
related to Turner syndrome, better oversight of all aspects of
healthcare, and the need for easy online access to information
and resources for patients living with Turner syndrome.
Synopsis from the professional panel discussions regarding
regional Turner syndrome resource centers. Philippe Back-
eljauw MD. A recent survey on the status of Turner syn-
drome clinics in the U.S. revealed that approximately 20–25
healthcare institutions identified the existence of such a subspe-
cialty clinic. The size and length of time these clinics have been in
existence varies considerably. Some of the institutions support a
true Turner syndrome center and are able to provide state-of-
the-art care through the involvement of multiple specialties, as
well as via the interactionwith patient support groups. Only a few
are also able to care for adults with Turner syndrome. The major
health and well-being issues and challenges currently facing girls
and women with Turner syndrome from a care provider per-
spective include:1. Proper transition of pediatric patients to adult care;2. Education regarding co-morbidities and preparedness for adult
care/life for patients with Turner syndrome, including repro-
ductive issues;3. Access to appropriate developmental, psychological and psy-
chiatric evaluation and therapy;4. Obtaining adequate health insurance coverage.
Several barriers to improving health and wellness for patients
with Turner syndrome have been identified:1. Lack of follow-up care;2. Lack of coordination of subspecialty care;3. Difficulty in identifying knowledgeable (adult) providers;4. Lack of uniform criteria for lifelong screening and care for
patients with Turner syndrome.
The professional panel envisions several regional, comprehen-
sive clinical centers. This could potentially lead to an integrated
national TS care network. An educational component could be part
of the TS clinic activities with patients and their families and local
TS support groups collaborating to increase TS awareness and
provide counseling. TS research could be integrated into a TRN,
through which the smaller TS clinics could feed into larger TS
resource centers. Quality improvement projects could be devel-
oped, as well as novel pilot research studies and multi-center
studies.TURNER SCIENCE: FROM GENOTYPE TO
PHENOTYPE
Estrogen Replacement in Adolescents With
Turner Syndrome. Nelly Mauras, MD
The proper timing, dose and more recently, route of estrogen
replacement in hypogonadal girls with Turner syndrome have been
better characterized in recent studies. Although historically, con-
jugated equine estrogens (CEE) had been the typical method of
estrogen replacement for patients with Turner syndrome and other
hypogonadal states in the U.S., CEE contains over 100 forms of
estrogens of different potencies and biological activity. Estradiol
(17bE2) is the most physiological estrogen available for replace-
ment as it is identical to the product of the intact gonad. It also has
the advantage that it can be accurately measured in plasma.
Micronized 17bE2 should be the preferred choice for feminizing
girls with different forms of hypogonadism. Most studies of the
metabolic effects of the different routes of estrogen administration
have used different types of estrogen, making comparisons across
studies difficult. We recently studied the metabolic effects of the
same form of estradiol, 17bE2 administered either orally or trans-
dermally, in a group of 40 girls with Turner syndrome in whom we
titrated the doses based on E2 concentrations obtained monthly,
measured by liquid chromatography—mass spectroscopy. We
aimed to achieve levels comparable to those of normally menstru-
ating adolescents measured in the same assay in both groups. All
subjects were cycled with progesterone monthly. After 12 months
of treatment, there were no differences between the groups for E2
concentrations, body composition, lean body mass, adiposity,
bone mass accrual or energy expenditure, LH/FSH suppression
or lipid concentrations. IGF-I concentrations trended lower in the
1968 AMERICAN JOURNAL OF MEDICAL GENETICS PART Atransdermal group, but still remained within normal range. How-
ever, there were considerable differences in the levels of estrone,
estrone sulfate and total bioestrogen concentrations (measured
using a recombinant cell bioassay), with levels much higher in the
oral group, creating an unphysiologic estrogen milieu. Both es-
trone and estrone sulfate can be stored in the adipocyte and breast
tissue and recycled back into E2 creating a reservoir of estrogen in
the body. These results are important, given the compelling body of
data that have accumulated on the increased thromboembolic
effects of oral over transdermal estrogens in both post- and pre-
menopausal women. Whether transdermal estrogen produces a
greater accumulation of other estrogen metabolites that can cause
DNA damage (genotoxic estrogens) awaits further study. We
concluded that adolescent girls with Turner syndrome should be
feminized at the normal physiologic time, preferably using trans-
dermal 17bE2 which produces a more physiologic milieu. The
therapeutic guidelines for estrogen replacement therapy in Turner
syndrome need to be revised.Early Abnormalities in Social, Attentional, and
Working Memory Circuits in Infants With Turner
Syndrome. Rebecca Knickmeyer, PhD
Adults and children with Turner syndrome differ from typical
female individuals with 46,XX karyotype in key components of
neural circuits for social cognition and working memory. Specifi-
cally, imaging studies demonstrate reductions in somatosensory
cortex and inferior parietal lobule, enlargement of the amygdalae
and insular and orbitofrontal cortex, altered white matter micro-
structure and disrupted frontoparietal circuitry in women with
Turner syndrome. Altered activation of the amygdala and caudate
during cognitive tasks also has been reported.What is not known is
when in development these relationships arise. This knowledge gap
is important, as it limits our ability to determine the appropriate
type and timing of behavioral interventions and hormone thera-
pies. Imaging of infants with Turner syndrome showed decreased
gray matter volumes in parietal cortex and increased gray matter
volumes in insular cortex when compared to female controls,
consistent with findings in older children. This suggests a stable
phenotype, with origins in the prenatal or early postnatal period.
Infants with Turner syndrome did not exhibit widespread changes
in white matter microstructure that have been reported in older
children, suggesting that early interventions might prevent or
ameliorate atypical white matter development in Turner syn-
drome. At 1 year of age, functional connectivity maps revealed
reduced fronto-parietal connectivity in infants with Turner syn-
drome, and increased connectivity with the insula. At age 2,
functional connectivity maps revealed a lack of typical connectivity
between caudate and frontal lobe in infants with Turner syndrome.
Extensive negative correlations with middle temporal gyrus were
present in infants with Turner syndrome, but not in controls.
Additional studies are needed to examine longitudinal changes in
brain structure and function in Turner syndrome, relate clinical
variables (such as genetic and hormonal variation) to brain devel-
opment, and test whether individual variation in neuroimaging
phenotypes predicts cognitive outcomes.Genetic and Epigenetic Mechanisms Underlying
Early Brain Development, Cognition, and
Behavior in TS. David S. Hong, M.D
Significant concerns for parents and individuals with Turner syn-
dromeare thepotential cognitive issuesassociatedwiththis condition.
Neuropsychological, genetic and neuroimaging studies indicate that
overall intelligence inTurner syndrome iswithin thenormative range.
However, specific cognitive sub-domainsmay represent areas of risk,
including visuospatial skills, executive function, arithmetic and social
cognition, while others may be relatively enhanced, such as verbal
skills. Significant gaps in currentunderstandingof cognitive aspects of
Turner syndrome still remain, particularly in regard to the correlation
between older neuropsychological findings and more recent genetic
and neuroimaging data, as well as a clearer view of the trajectory of
cognitive development in Turner syndrome over the lifespan. Recent
studies may provide further insight into developmental issues related
toTurner syndrome, including thefirst concrete evidence for aberrant
longitudinal trajectoriesofneurodevelopment, confirming thecritical
need for using lifespan studies to better delineate dynamic changes in
brain growth patterns across various stages of development. It is
important to understandhow these brain findings relate to long-term
adaptiveoutcomes.Understanding thegenotype-phenotype relation-
ships between genes on the X chromosome and brain development is
also important. Findings include evidence of imprinting, an epige-
netic mechanism related to parental origin of genetic material. Girls
who have 45,X karyotype with a paternally-derived X chromosome
perform less well in the performance IQdomain relative to peers with
a maternally-derived X chromosome, a finding which may reflect a
neurobiological basis for observed cognitive differences between these
two cohorts. Additionally, X chromosome “dosage” may have a
specific effect on brain development, with the number of sex chro-
mosomes linearly correlated to brain volumes in the temporal and
parietal lobes. In totality, advances in neuroimaging and genetic
technologies over the past decade have significant potential to expo-
nentially increase our understanding of cognition and neurodevelop-
ment in Turner syndrome.
Genetic Basis of Bicuspid Aortic Valve in Turner
Syndrome. Siddharth K. Prakash, MD, PhD
Bicuspid aortic valve (BAV) is the most common congenital heart
defect. BAV is caused by the failure of two or more cusps to separate
during late stagesofembryonicdevelopment.TheprevalenceofBAVis
increased more than 30-fold in women with Turner syndrome, who
are at greatly increased risk for acute aortic dissections. Girls and
women with Turner syndrome require operations for significant left
heart obstructive disease far more than those without the condition.
We hypothesize that at least two genetic hits are required for suscepti-
bility to aortic disease in Turner syndrome. The first hit may be a
reduction in thedosageofXchromosomegenesdue toXchromosome
structural variation in Turner syndrome. A second hit could be a
commonvariantoramodifierallele thatdoesnotcausediseaseby itself
but may interact with reduced X chromosome dosage to account for
the prevalence of BAVs in womenwith Turner syndrome. To test our
hypothesis, weperformed a genome-wide association study inwomen
with Turner syndrome comparing those with BAV to those with
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peaks on chromosomes 4, 18, and 22, with a minimum P-value of
1 107. We also confirmed that BAV is strongly associated with the
dosage, but not the genotypes of single nucleotide polymorphisms on
the short arm of the X chromosome (Xp) and used breakpoint
mapping to identify several new candidate Xp genes for BAV. These
findings are consistentwithourhypothesis thatBAVmaybe causedby
reduced X chromosome dosage in women with Turner syndrome, as
well asmen in the general population, andopensnewavenues forBAV
gene discovery.Insights into Congenital and Ischemic Heart
Disease From Studies in Turner Syndrome.
Carolyn Bondy, MS, MD
Five hundred girls and women with rigorously established Turner
syndrome karyotypes were examined with cardiac MRI as well as
transthoracic ultrasound. These imaging studies show that approxi-
mately 50% of study subjects had an abnormal elongation of the
transverse portion of the aortic arch (ETA). This anomaly is associated
withadistinctivekink in the lesser curvatureandbulbousdilationof the
left subclavian artery origin in the region usually involved in aortic
coarctation. The specific anatomic alterations of defective aortic valve
and aortic coarctation were exclusively found among those with ETA.
While the bicuspid aortic valve was found in 30% of the general study
population, it was found in 60%of thosewith the ETA, suggesting that
haploinsufficiency for unknown X/Y chromosomal gene(s) caused
abnormal aortic arch development, which secondarily led to defective
aortic valve development, and likely also to aortic coarctation, possibly
due to severely abnormal blood flow patterns in the developing aortic
arch.Thispossibility is supportedby thefindingof severe abnormalities
of the transverse arch (interruption or tubular hypoplasia) in 45,X
fetuses or newborns that succumbed to cardiovascular defect. Genetic
studies of the congenital cardiovascular phenotype mapped the phe-
notype to the short arm of the X chromosome, telomeric to Xp.11.4
(and homologous gene(s) present on Yp). Congenital defects were
equally prevalent in groups with a single X chromosome derived from
the mother or the father, indicating that genomic imprinting does not
contributetotherisk forcongenitalcardiacdefects inTurnersyndrome.
We investigated deposits of calcium in the coronary arteries of groups
monosomic for amaternal versus paternal X chromosome, and found
that the coronary calcium was abundant in women with a maternal X
(similar to age-matchedpopulationmen from the Framingham study)
and totally absent from the coronaries of women with a paternal X,
suggesting that the presence of a single maternal X chromosome is an
independent risk factor for atherosclerotic coronary disease.Genomic Approaches to Understanding
Congenital Cardiac Anomalies in Congenital
Heart Disease (CHD) in Turner Syndrome, Paul
Kruszka, MD
Congenital heart disease occurs in almost half of girls and women
with Turner syndrome and is a leading cause of morbidity and
mortality. Bicuspid aortic valve occurs in over 30% of individualswith Turner syndrome and aortic coarctation occurs in approxi-
mately 12%. Aortic dissection, the most catastrophic anomaly, is
increased more than 100-fold in Turner syndrome. Previous
studies suggest that a genetic culprit is located on the short arm
of the X chromosome (Xp); however, a single gene, or group of
genes, causing CHD in Turner syndrome have yet to be found. The
most popular hypothesis is that haploinsufficiency of the pseu-
doautosomal region (PAR1) genes or other genes on Xp that have
homologues on the Y chromosome contribute to the cause of CHD.
Unfortunately, an adequate animal model for CHD in Turner
syndrome does not exist, as the XO mouse does not have heart
defects.
Maximilian Muenke at the National Human Genome Research
Institute, the National Institutes of Health (NIH) is conducting
whole exome sequencing in girls and women with Turner syn-
drome in an effort to better understand the genetic and molecular
underpinnings of cardiac disease in this condition. Additionally,
new gene editing techniques and animal models of Turner syn-
drome are being developed to couple gene discovery in humans
with functional analyses. This multidisciplinary approach to re-
search in Turner syndrome is directed at developing mechanistic
insights into CHD in the condtion and provides an avenue for the
development of new diagnostic and therapeutic capabilities in the
future.
CROSSROADS OF HEALTH POLICY AND RESEARCH:
ROADMAP TOWARD THE TRN
Securing a National Turner Syndrome Program
in an Era of Declining Federal Resources. David
A. Cole, PhD
Building a robust TRN is a worthy goal, but one that will require
substantial financial resources—resources in excess of those cur-
rently raised by the Turner Syndrome Society (TSSUS) and the
Turner Syndrome Foundation (TSF) combined. The TRNwill face
challenges in the form of several key scientific and philanthropic
trends: a) NIH and National Science Foundation grant making,
especially for basic scientific investigation, is falling victim to
federal budget cutting; b) corporate grant making is on the decline
and increasingly tied to companies’ marketing objectives; c) cor-
porate and foundation grantmakers are allocating fewer dollars for
indirect cost recovery; d) the time required to apply for, and
steward, institutional grants is increasing; and e) grant makers
are fielding record numbers of applications and making smaller
grants. One additional philanthropic trend, however, suggests
another, more promising approach: substantial sums, allocated
by individuals for philanthropy, are increasingly being channeled
into private foundations and donor advised funds (DAFs). TSSUS
and TSF should consider pooling their resources and investing in a
major gifts fundraiser. The centrally coordinated resources of
TSSUS/TSF could be directed toward the following activities: 1)
leveraging existing ties to TSS/TSF supporters and members to
identify, and build new relationships; 2) developing a major gifts
“moves management” function within TSSUS/TSF to coordinate
prospect identification, cultivation, applications, and gift/grant
stewardship on a national level. This function would ensure that
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the TRN network; 3) ensuring that TSSUS/TSF establish and
maintain a major gifts focus on their common website, on social
media, and in related communications collateralSuccessful Models for Conceiving,
Implementing, and Conducting Multi-Center
Research. Victoria Pemberton, RNC, MS
Like other rare diseases, clinical care and research in Turner
syndrome faces similar challenges related to the small number
of affected individuals seen at any given institution; heterogeneity
of care practices, and physicians’ and patients’ limited experiences
of participating in research. Networks or “Collaboratories,” com-
posed of multiple research centers, are likely necessary for the
effective conduct of clinical research with adequate numbers of
patients to meet sample size requirements. Key elements for a
successful TRN were identified and include standardization of
research procedures, multidisciplinary working relationships,
shared learning regarding mistakes and successes, open access to
researchers with important study proposals, integrating research
with clinical care, and central monitoring and oversight. The TRN
must nurture partnerships with patient advocacy groups as these
groups serve as conduits for education among theirmembers about
the importance of research, they provide insight into potential
study questions, highlighting those that are most critical to indi-
viduals with Turner syndrome, and they provide support and
resources such as potential research participants, educational
information, financial support, and political advocacy on behalf
of the TRN. An effective infrastructure must consider leveraging
funding opportunities with government agencies, pharmaceutical
companies, foundations, advocacy groups and investigators with
similar interests. An important mission for the TRN will be to
discern the “extended opportunities” that can lead to therapies and
interventions for both Turner syndrome and other populations.TRN Roadmap Synopses (6 breakout sessions)
How theTurner resource network steering committee should be
organized. There should be a start-up steering committee, a
working group tasked with calling for proposals, establishing
criteria for the regional centers, and developing policies and
procedures for how the network would operate. The group should
be multidisciplinary and should also have family advocates/wom-
en living with Turner syndrome represented. The group must
represent all of the diversity of opinions and thoughts within
the TRN.
How will the TRN patient-powered registry be designed?.
How the information will be accessed needs to be determined. The
registry committee should include families and lay advocates
alongside clinicians and researchers. This group will decide the
areas of focus, what important outcomes should be, the types of
data that should be collected, and how the informationwill be used.
The existing NHLBI-sponsored National Registry of Thoracic
Aortic Aneurysms and Related Conditions (GenTAC) contains
over 300 subjects with Turner syndrome for whom extensivecardiovascular data, both cross-sectional and longitudinal, have
been collected [Kroner et al., 2011]. When the TRN registry
incorporates the GenTAC Turner data it will be research ready.
An application to the PCORI patient-powered research network
(PPRN) [Daugherty et al., 2014] is planned. Transparency regard-
ing how the Turner database can be used for research purposes will
be necessary. Key questions without necessarily supplying specific
answers were posed: What kind of data beyond the GenTAC
cardiovascular component will be collected—longitudinal or
cross-sectional, retrospective or prospective? What domains of
data general health, genetics, phenotype, and demographics
need to be included? Should the data be comprehensive, agnostic
or hypothesis-driven? Will it serve as a resource to both “TRN
investigators” and outside individuals or organizations? What
areas of datawill be collected in a standardized fashion? Possibilities
include: endocrine including reproductive endocrine, cardiovas-
cular, genetics, and neurobiological, including cognition? Will the
coordinating center serve as bio-repository of genetic data, imaging
data?Will the coordinating center serve as bio-repository of genetic
data, imaging data? A group volunteered to further consider the
question going forward.
How will the Turner resource network be funded?. Without
the aligned support of the threemajor advocacy groups, the Turner
Syndrome Society of the United States, the Turner Syndrome
Foundation and the Turner Syndrome Global Alliance, the TRN
will not succeed. It is through the membership of these organiza-
tions that avenues for philanthropic support will become apparent.
Perhaps needed services, informatics/database support, can be
obtained by soliciting contributions from a large group of people,
and especially from an online community (“crowdsourcing”) may
be an option. Employing a professional skilled in philanthropic
activities will be necessary. Funding opportunities from all poten-
tially receptive health organizations will be explored. In particular,
requests for applications to the Patient Centered Outcomes Re-
search Initiative (PCORI) will be primarily considered.
What is the ideal regional resource center?. The focus should
be the regional Turner syndrome clinic. The key to success for these
clinics is coordination of care for the individual living with Turner
syndrome. A successful clinic will be a platform through which
research can be performed. The clinic will require designated
standards and some measures to evaluate each clinic’s success.
Primary care coordination will require at the very least, cardiology,
endocrinology, and neuro-developmental expertise. The action
item is to publish the current matrix of 25 Turner regional centers
collated by Dr. Angela Lin, and to develop a working group to
establish the criteria for designation as a regional resource center.
Which Turner syndrome guidelines need to be revisited?. The
guidelines overall should be updated. Consideration should be
given to publishing guidelines on a specific subtopic as a way of
tackling the larger issue of guidelines updates. Consideration
should be given to taking an age-related life span approach (fetus,
infant, child, adolescent, and adult). Lay versions of the guidelines
should be created. There are a number of pressing specific ques-
tions: Which sex steroid replacement therapies and the timing,
dosage and other issues of sex steroid therapy need to be clarified?
Turner syndrome diagnosis options and their utilization/timing
need to be defined (karyotype vs. microarray, newborn screening).
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clarified. The indications for echocardiography versus MRI for
cardiovascular disease are unclear. Dosing and timing of rhGH
therapy recommendations should be studied further. What are the
indications, contraindications, and relative contraindications for
pregnancy? What screening tests are needed prior to pregnancy? A
pregnancy consent form should be considered as a way to precipi-
tate a thorough discussion about potential risks. Guidelines for
fertility preservation need to be established. Indications for cogni-
tive assessment and their relative value are unclear.
How will the Turner resource network research project be
reviewed?. Funds within the TRN will be available for research
projects. In addition, investigators with their own fundswill wish to
take advantage of TRN resources for Turner syndrome-related
projects. The major factor determining research priorities overall
will be the best science that meets the priorities as set by the TRN
scientific advisory committee.
CONCLUSIONS
Morbidity andmortality in Turner syndrome is unacceptably high.
The TRN needs to help find ways to improve health policy and
health care delivery for girls and women living with Turner
syndrome by: 1) creating nationally coordinated regional resource
centers linked by a patient-powered registry; 2) conducting high
quality outcomes-based clinical research; and 3) supporting basic
Turner science programs. The research community in general
needs to step up in terms of efforts to understand sex-chromosome
biology, its deep biology in all of its complexity, so that we can
better understand the clinical and personal ramifications of living
with Turner syndrome. We must also elucidate the role of the X
chromosome in common disease susceptibility in the general
population. A concerted effort by the NIH, national medical/
scientific foundations and societies, as well as the pharmaceutical
industry is necessary to bring the sex chromosomes back to the
forefront of research. The TRN can encourage and promote this
process by engaging in research in Turner syndrome.
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